Market Overview
The Glycerin Trinitrate Market is estimated to reach at a Significant CAGR during the forecast period (2024-2031).
Glyceryl trinitrate (GTN), is a type of medicine called nitrate. It is used to treat chest pain known as angina. If an angina attack has already started glyceryl trinitrate can help stop chest pain. It also helps to prevent them from starting.
Market Scope
| Metrics | Details |
| Market CAGR | Prominent Growth |
| Segments Covered | By Drug Type, By End User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Insights: Download Sample
Market Dynamics
The increasing incidence rate of angina and increased need for proper blood flow will drive the glycerin trinitrate market.
The increasing incidence rate of angina will drive the glycerin trinitrate market
Angina prevalence varied widely, from 0.73% to 14.4% (population-weighted mean 6.7%) in women and from 0.76% to 15.1% (population-weighted mean 5.7%) in men. The causes of angina pectoris are poorly understood. Despite stable angina being a common initial presentation of coronary disease1 and exerting a major impact on quality of life, ability to work, and costs to society, there have been few large-scale epidemiological investigations and no meta-analyses of risk factors angina. Angina is a common condition, more in men than in women. Socioeconomically deprived patients are more likely to have angina but are less likely to consult their general practitioner. Guideline‐recommended treatments for angina are underused in women and older patients.
Glyceryl trinitrate (GTN) is a type of medicine called nitrate. It is used to treat chest pain known as angina. It is used to treat symptoms of angina, such as chest pain or pressure when there is not enough flow of blood to the heart. To improve blood flow to the heart, nitroglycerin opens up (dilates) the arteries in the heart (coronary arteries), improving symptoms and reducing how hard the heart has to work.
Increased need for reduced blood pressure will drive the glycerin trinitrate market
Blood pressure (BP) is elevated in 75% of patients presenting with acute ischaemic stroke1 and is associated independently with poor clinical outcomes. Lowering elevated BP appears safe in acute ischaemic stroke but has failed to show clinical benefit. The acute effect of glyceryl trinitrate (GTN) is mainly the reduction of systolic blood pressure (SBP) rather than diastolic blood pressure (DBP).
Nitroglycerin is a potent venodilator, showing arterial dilation only at very high doses. Sublingual, topical or IV nitroglycerin infusion is recommended as a first-line agent in blood pressure control in acute hypertensive pulmonary oedema and acute coronary syndrome due to its favourable effect in reducing preload and cardiac output. It is useful as a second-line agent in hypertensive emergencies due to acute sympathetic crisis (as in cocaine, amphetamines, monoamine oxidase inhibitor toxicities, Irukandji Syndrome). The recommended mean arterial pressure (MAP) reduction in these conditions is up to 25% for the first 24 h, and over-reduction might cause end-organ ischemia and more harm.
Side effects will hamper the glycerin trinitrate market
Glyceryl trinitrate spray is used to treat and prevent heart-related chest pain (angina). Angina or chest pain occurs when the heart muscle does not get enough blood. The medicine works by relaxing and widening blood vessels so that blood can flow easily to the heart. It has a very short-lived effect. At the first sign of chest pain the spray should be taken. It should be used in the duration and dose as advised by doctor. Medical help should be taken immediately if pain continues for more than 15 minutes. Some people are advised to use this medicine before any exercise or exertional activity, which may trigger angina.
The common side effect of this medicine which may be severe is a headache. It can sometimes be helped by drinking a lot of fluids and avoiding alcohol. One may also experience lightheadedness, which could increase the risk of having a fall. This medicine should not be taken when the person is taking medicines to treat high blood pressure in lungs (pulmonary hypertension) or glaucoma (increased pressure inside the eye) or anemia or erectile dysfunction.One should always inform doctor what other health conditions and what other medicines theyare taking. It is recommended to consume alcohol with this medicine as it increases some of the side effects. If one is affected by dizziness, avoid driving. If one is pregnant, thinking about becoming pregnant, or breastfeeding, they should ask doctor before taking this medicine.
Industry Analysis
COVID-19 Impact Analysis On Market
COVID-19 has affected the healthcare industry. To curb its growth, government-imposed lockdown. People are fearful they will experience occupational effects and adverse health from the COVID-19 pandemic. This affects the glycerin trinitrate market as many pharmaceutical industries have stopped manufacturing units.
Market Segment Analysis
Tablets segment will dominate the glycerin trinitrate market
Glyceryl Trinitrate or GTN belongs to a group of medicines called nitrate vasodilators. They work by relaxing the blood vessels of the heart. This reduces the strain on the heart by making it easier to pump blood. Glyceryl Trinitrate tablets, which are given under the tongue, treat chest pain caused by coronary heart disease known as acute angina pectoris.
Both Lycinate and Anginine share the same formulation, including the new formulation available in a circular tablet. Till date, the reports of difficulty in breaking tablets in half and longer than expected time to dissolve have related to the new formulation of GTN tablets. TGA with the current sponsor Arrow Pharmaceuticals is working and the previous sponsor, Aspen Pharma, to investigate this issue.
The hospital segment will dominate the glycerin trinitrate market
Glyceryl trinitrate (GTN), is a type of medicine called nitrate. It is used to treat angina (chest pain). It can help stop chest pain if an angina attack has already started. It can also help to prevent them from starting. GTN ointment can also be used to treat tears in the skin around your bottom (anal fissures). It comes as tablets or as a spray that you put under your tongue. It also comes as patches and ointment that you put on your skin. Sometimes GTN patches are used in the hospital to make your veins easier to see if you need to have a drip (infusion). GTN is available on prescription. The Glyceryl trinitrate tablets are used in acute healthcare settings such as hospitals.
Patient should check that whether GTN spray is working by pressing the pump button a few times to produce a fine mist of liquid before using it for the first time. The patient should aim the spray onto a tissue or similar item when they need to use it inorder to aim it correctly under the tongue.The spray needs to be checked regularly to see if it works properly if the patient does not use the spray very often.The patient should rest in the sitting position ideally during its application. With the valve head uppermost the canister should be held vertically and the spray orifice should be close to the mouth as possible. The dose is sprayed under the tongue and the mouth should is closed immediately after each dose. The spray is not be inhaled. Patients are instructed to familiarise themselves with the position of the spray orifice, which the finger rest can identify on top of the valve to facilitate orientation for the administration at night. Hence, with all the instructions to follow while using glyceryl trinitrate, it's safe to be used in a hospital setting. This segment will dominate the market.
Market Geographical Share
North America region will dominate the glycerin trinitrate market
This region will dominate the glycerin trinitrate market with increased research and development activity and major key player's presence.
Annually around 9.8 million Americans are estimated to experience angina, every year with 500,000 new cases of angina occurring. An estimated 785 000 Americans in 2009 will have a new coronary attack and about 470 000 will have a recurrent attack. Only 18% of coronary attacks are preceded by angina. An additional 195,000 silent first myocardial infarctions are estimated to occur each year.
Due to the critical shortage of Nitroglycerin in 5% Dextrose Injection products in the United States (US) market, Arbor Pharmaceuticals, LLC (Arbor) is coordinating with the Food and Drug Administration (FDA) to increase the availability of Nitroglycerin by 5% Dextrose Injection products. In cooperation with the FDA, Arbor has initiated temporary importation of non-FDA approved Nitronal (glyceryl trinitrate) Infusion solution, 1 mg/mL, from G. POHL BOSKAMP GmbH & Co. KG, Germany, into the US market.
Market Companies
Major key players in the glycerin trinitrate market are Dipharma, Credo Life, Bharat Pharma, Guangzhou Tosun Pharmaceutical, Precise Group, Shanghai Hegno Pharmaceutical Holding Co., Ltd., Jiangxi Tianxin Pharmaceutical Co. Ltd. and Nanjing Pharmaceutical Factory Co. Ltd.
Glycerin Trinitrate Market. Key Companies to Watch
Dipharma
Overview: A global CDMO and a leading manufacturer of Active Pharmaceutical Ingredients Dipharma Inc. is a wholly-owned subsidiary of Dipharma Francis S.r.l. serving a large base of pharmaceutical companies worldwide. Founded in 2012, Dipharma Inc. provides direct support to US customers, and it is focused on developing new business opportunities in the North American market.
Product Portfolio: The company is engaged in APIs manufacturing and Custom Synthesis.
Key Development:
Dipharma Francis S.r.l., (Dipharma), a leading European manufacturer of Active Pharmaceutical Ingredients has completed its previously announced acquisition of a world-class Contract Research Organization (CRO) Kalexsyn, Inc. (Kalexsyn), providing chemistry services to the biotechnology and pharmaceutical industry.
The Glycerin Trinitrate Market report would provide an access to an approx. 53 market data table, 43 figures and 200 pages.
